Jorg Vollmer

Summary

Affiliation: Coley Pharmaceutical Group

Publications

  1. ncbi C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level
    Marion Jurk
    Coley Pharmaceutical GmbH, Elisabeth Selbert Str 9, D 40764 Langenfeld, Germany
    Immunobiology 209:141-54. 2004
  2. doi Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
    Jorg Vollmer
    Coley Pharmaceutical GmbH, A Pfizer Company, Dusseldorf, Germany
    Adv Drug Deliv Rev 61:195-204. 2009
  3. pmc Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers
    Curtis L Cooper
    Coley Pharmaceutical Canada, Ottawa, Canada
    J Immune Based Ther Vaccines 6:3. 2008
  4. doi In vitro effects of adjuvants on B cells
    Jorg Vollmer
    Coley Pharmaceutical GmbH, A Pfizer Company, Dusseldorf, Germany
    Methods Mol Biol 626:131-48. 2010
  5. ncbi Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9
    Jorg Vollmer
    Coley Pharmaceutical GmbH, Elisabeth Selbert Str 9, 40764 Langenfeld, Germany
    Expert Opin Biol Ther 5:673-82. 2005
  6. ncbi TLR9 in health and disease
    Jorg Vollmer
    Coley Pharmaceutical, GmbH, Langenfeld, Germany
    Int Rev Immunol 25:155-81. 2006
  7. pmc Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation
    Jorg Vollmer
    Coley Pharmaceutical, Langenfeld, Germany
    Immunology 113:212-23. 2004
  8. ncbi Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity
    Jorg Vollmer
    Coley Pharmaceutical, Elisabeth Selbert Str 9, 40764 Langenfeld, Germany
    J Leukoc Biol 76:585-93. 2004
  9. pmc Immunopharmacology of CpG oligodeoxynucleotides and ribavirin
    Jorg Vollmer
    Coley Pharmaceutical GmbH, Elisabeth Selbert Strasse 9, D 40764 Langenfeld, Germany
    Antimicrob Agents Chemother 48:2314-7. 2004
  10. ncbi Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA)
    Jorg Vollmer
    Coley Pharmaceutical Group, D 40764 Langenfeld, Germany
    Oligonucleotides 14:23-31. 2004

Collaborators

Detail Information

Publications28

  1. ncbi C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level
    Marion Jurk
    Coley Pharmaceutical GmbH, Elisabeth Selbert Str 9, D 40764 Langenfeld, Germany
    Immunobiology 209:141-54. 2004
    ..These characteristics can be availed to induce potent anti-tumor or anti-viral effects. Consequently, C-Class CpG ODN represent ideal drug candidates for anti-viral and/or anti-tumor therapy...
  2. doi Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
    Jorg Vollmer
    Coley Pharmaceutical GmbH, A Pfizer Company, Dusseldorf, Germany
    Adv Drug Deliv Rev 61:195-204. 2009
    ..Although their potential clinical contributions are enormous, the safety and efficacy of these TLR9 agonists in humans remain to be determined...
  3. pmc Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers
    Curtis L Cooper
    Coley Pharmaceutical Canada, Ottawa, Canada
    J Immune Based Ther Vaccines 6:3. 2008
    ..A potent immune activator such as TLR9 agonist CpG oligodeoxynucleotide (CpG) may complement current treatment approaches...
  4. doi In vitro effects of adjuvants on B cells
    Jorg Vollmer
    Coley Pharmaceutical GmbH, A Pfizer Company, Dusseldorf, Germany
    Methods Mol Biol 626:131-48. 2010
    ..Here, we will try to give an overview on the TLR expression pattern of human, primate, and murine B cells, their stimulation by TLR ligands or other adjuvants, and the outcome such as B cell proliferation and cytokine production...
  5. ncbi Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9
    Jorg Vollmer
    Coley Pharmaceutical GmbH, Elisabeth Selbert Str 9, 40764 Langenfeld, Germany
    Expert Opin Biol Ther 5:673-82. 2005
    ..TLR9 agonists represent a new class of small (8-30 bases long), easily synthesised, non-antisense ODN pharmaceuticals...
  6. ncbi TLR9 in health and disease
    Jorg Vollmer
    Coley Pharmaceutical, GmbH, Langenfeld, Germany
    Int Rev Immunol 25:155-81. 2006
    ..This review will summarize the interplay between TLR9-dependent opposing stimulatory and regulatory effects in innate and adaptive immunity...
  7. pmc Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation
    Jorg Vollmer
    Coley Pharmaceutical, Langenfeld, Germany
    Immunology 113:212-23. 2004
    ..Our study indicates that TLR9 can mediate either efficient Th1- or Th2-dominated effects depending on whether it is stimulated by CpG or certain non-CpG ODN...
  8. ncbi Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity
    Jorg Vollmer
    Coley Pharmaceutical, Elisabeth Selbert Str 9, 40764 Langenfeld, Germany
    J Leukoc Biol 76:585-93. 2004
    ..These studies provide a structure-activity relationship for TLR9 agonist compounds with diverse immune effects...
  9. pmc Immunopharmacology of CpG oligodeoxynucleotides and ribavirin
    Jorg Vollmer
    Coley Pharmaceutical GmbH, Elisabeth Selbert Strasse 9, D 40764 Langenfeld, Germany
    Antimicrob Agents Chemother 48:2314-7. 2004
    ..CpG ODN represent a promising new type of therapeutic drug for hepatitis C or other infectious diseases...
  10. ncbi Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA)
    Jorg Vollmer
    Coley Pharmaceutical Group, D 40764 Langenfeld, Germany
    Oligonucleotides 14:23-31. 2004
    ..These data indicate that increasing amounts of LNA residues in the flanks or substitutions of CpG nucleobases with LNA reduce or eliminate the immune stimulatory effects of CpG-containing phosphorothioate ODN...
  11. ncbi Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities
    Jorg Vollmer
    Coley Pharmaceutical Group, Langenfeld, Germany
    Eur J Immunol 34:251-62. 2004
    ..In vivo studies demonstrate that C-Class ODN are very potent Th1 adjuvants. C-Class ODN may represent new therapeutic drugs that combine the effects of A- and B-Class ODN for broad applications in infectious disease or cancer therapy...
  12. ncbi CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells
    Jorg Vollmer
    Coley Pharmaceutical GmbH, Langenfeld, Germany
    J Endotoxin Res 10:431-8. 2004
    ..Our data provide a better understanding of the mechanisms through which CpG ODNs induce efficient Th1 responses...
  13. ncbi Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses
    Alexandra Forsbach
    Coley Pharmaceutical GmbH, Dusseldorf, Germany
    J Immunol 180:3729-38. 2008
    ..In summary, we describe two classes of single-stranded TLR7/8 and TLR8 RNA agonists with diverse target cell and species specificities and immune response profiles...
  14. doi A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties
    Ulrike Samulowitz
    Coley Pharmaceutical GmbH A Pfizer Company, Dusseldorf, Germany
    Oligonucleotides 20:93-101. 2010
    ..Taken together, we have discovered a novel class of CpG ODNs, the P-Class, with promising superior activity for disease application...
  15. pmc Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8
    Jorg Vollmer
    Coley Pharmaceutical GmbH, 40764 Langenfeld, Germany
    J Exp Med 202:1575-85. 2005
    ..These results demonstrate that a prototype autoantigen, the snRNP, can directly stimulate innate immunity and suggest that autoantibodies against snRNP may initiate SLE by stimulating TLR7/8...
  16. doi Dual or triple activation of TLR7, TLR8, and/or TLR9 by single-stranded oligoribonucleotides
    Alexandra Forsbach
    Pfizer Oligonucleotides Therapeutics Unit, Coley Pharmaceutical GmbH, Dusseldorf, Germany
    Nucleic Acid Ther 21:423-36. 2011
    ....
  17. doi Immunostimulatory potential of silencing RNAs can be mediated by a non-uridine-rich toll-like receptor 7 motif
    Marion Jurk
    Pfizer Oligonucleotide Therapeutics Unit, Coley Pharmaceutical GmbH, Merowingerplatz 1a, Dusseldorf, Germany
    Nucleic Acid Ther 21:201-14. 2011
    ..Our findings are of therapeutic relevance as this motif is present in many siRNA sequences and will to contribute to the immunostimulatory properties of unmodified siRNAs...
  18. ncbi Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists
    Marion Jurk
    Coley Pharmaceutical GmbH, Elisabeth Selbert Strasse 9, 40764 Langenfeld, Germany
    ChemMedChem 1:1007-14. 2006
    ..In addition, we found significant species-specific differences between human and murine TLR9 recognition, which demonstrates the importance of choosing appropriate assay systems for SAR studies...
  19. doi Negative regulation of the type I interferon signaling pathway by synthetic Toll-like receptor 7 ligands
    Alexandra Forsbach
    Pfizer Oligonucleotide Therapeutics Unit Coley Pharmaceutical GmbH, Dusseldorf, Germany
    J Interferon Cytokine Res 32:254-68. 2012
    ..These findings provide novel insights into the use of synthetic TLR7 or TLR7/8 small molecules as ligands for immune activation and suppression...
  20. ncbi Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides
    Marion Jurk
    Coley Pharmaceutical GmbH, Langenfeld, Germany
    Eur J Immunol 36:1815-26. 2006
    ..These results demonstrate an unexpected plasticity in the ligand specificities of TLR7 and TLR8, and suggest a novel sequence-selective interaction between these receptors and synthetic phosphorothioate ODN...
  21. doi Impact of delivery systems on siRNA immune activation and RNA interference
    Alexandra Forsbach
    Coley Pharmaceutical GmbH, Merowingerplatz 1a, 402254 Düsseldorf, Germany
    Immunol Lett 141:169-80. 2012
    ..Superfect delivery system only activates TLR7 and opens new capabilities in RNAi and immune activation...
  22. pmc Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment
    Denise Richardt-Pargmann
    Pfizer Oligonucleotide Therapeutics Unit OTU, Coley Pharmaceutical GmbH, Merowingerplatz, Dusseldorf, Germany
    Immunobiology 216:12-23. 2011
    ..Our results strongly suggest that co-stimulation of T cell proliferation by TLR7/8 agonists is dependent on the specific cellular context...
  23. ncbi Characterization of conserved viral leader RNA sequences that stimulate innate immunity through TLRs
    Alexandra Forsbach
    Coley Pharmaceutical GmbH, Dusseldorf, Germany
    Oligonucleotides 17:405-17. 2007
    ....
  24. ncbi Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes
    Jorg Vollmer
    Coley Pharmaceutical GmbH, Langenfeld, Germany
    Antisense Nucleic Acid Drug Dev 12:165-75. 2002
    ..Such ODNs can induce effects similar to those seen with CpG ODNs but are much less efficient in stimulating human immune cells...
  25. ncbi Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9
    Christian Schetter
    Coley Pharmaceutical GmbH, Elisabeth Selbert Strasse 9, D 40764 Langenfeld, Germany
    Curr Opin Drug Discov Devel 7:204-10. 2004
    ....
  26. ncbi Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity
    Arthur M Krieg
    Coley Pharmaceutical Group Inc, Wellesley, MA, USA
    Immunol Rev 220:251-69. 2007
    ..Finally, with the rapid progress in the development of therapeutic agonists for the TLRs, there is accompanying attention to the theoretical possibility that such therapy may induce autoimmunity or autoimmune diseases...
  27. doi Stimulation of the immune system by therapeutic antisense oligodeoxynucleotides and small interfering RNAs via nucleic acid receptors
    Denise Richardt-Pargmann
    Coley Pharmaceutical GmbH A Pfizer Company, Dusseldorf, Germany
    Ann N Y Acad Sci 1175:40-54. 2009
    ..In some cases, synthetic ODN and ORN can trigger these defenses and, therefore, can interfere with or distort the mechanism of action of antisense ODN or small interfering RNAs...
  28. ncbi Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation
    Marion Jurk
    Coley Pharmaceutical GmbH, Dusseldorf, Germany
    BioDrugs 21:387-401. 2007
    ..Therefore, CpG ODNs represent targeted immune modulatory drugs with a broad range of potential applications...